Bharat Parenterals Ltd
Bharat Parenterals Q4 FY24 earnings call: Revenue & Margins
Q4 FY24 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹68Cr
- +33.1% YoY
- Net profit
- −₹3Cr
- Q4 FY23: ₹2 Cr
- Margin
- 1.47%
- −10.7 pp YoY
Guidance rank: #10 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Bharat Parenterals Ltd's Q4 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
For Q4 FY 2024, consolidated revenue from operations was INR 67.82 crore, up 13.4% YoY (Q4 FY 2023: INR 59.82 crore). Quarter (Q4 FY 2024) Financials (Consolidated): - EBITDA: ₹3.64 crore, down 53.7% YoY (₹7.87 crore in Q4 FY 2023) - EBITDA margin: 5.17%, down from 12.88% YoY - PAT: -₹2.56 crore, a decrease o
From Bharat Parenterals Ltd's Q4 FY24 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- For Q4 FY 2024, consolidated revenue from operations was INR 67.82 crore, up 13.4% YoY (Q4 FY 2023: INR 59.82 crore).
- Consolidated total operating revenue for Q4 FY 2024 was INR 70.46 crore, compared to INR 61.08 crore in Q4 FY 2023.
- Standalone revenue from operations for Q4 FY 2024 was INR 65.64 crore, up 28.8% YoY (Q4 FY 2023: INR 50.97 crore).
- Standalone total operating revenue for Q4 FY 2024 was INR 68.88 crore versus INR 57.9 crore in Q4 FY 2023.
2 more points from Bharat Parenterals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Bharat Parenterals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Commissioning of two new EU GMP compliant production blocks (Page 15)
- Status: Inspection and compliance completed; pending approval
- Expected to enable access to multiple APAC geographies
- Regulatory approvals underway for Uganda Ministry of Health for existing blocks; plans to obtain approvals in Ethiopia and Tanzania (Page 15)
- Infrastructure expansion planned to develop specialty products: lines for lyophilized, pre-filled syringes, and complex emulsion formulations (Page 14)
2 more points from Bharat Parenterals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Bharat Parenterals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Bharat Parenterals Ltd — Quarterly revenue & net profit
Bharat Parenterals Ltd Q4 FY24 results — key figures
| ₹ Cr | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue | 68 | 51 | +33.1% | 60 | +13.4% |
| Operating profit (EBITDA) | 1 | 6 | -83.9% | 7 | -84.9% |
| Operating margin | 1.47% | 12.2% | -10.7 pp | 11.05% | -9.6 pp |
| Profit before tax | -1 | 4 | -131.7% | 5 | -124.9% |
| Net profit (PAT) | -3 | 2 | -212.8% | 4 | -170.3% |
| EPS (₹) | -0.52 | 4.31 | -112.1% | 6.50 | -108% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹100 Cr, net loss ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Bharat Parenterals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY24)
1,759 Cr, a 5% YoY increase from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.
- Themis Medicare (Q4 FY24)
97.82 Cr, up 22.11% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.
- Fermenta Biotech (Q4 FY24)
Q4-FY24 Consolidated Operational Revenue: INR 973 Mn, down 7.5% YoY (Page 11) . Key concall takeaways from Fermenta Biotech Ltd's Q4 FY24 earnings call — and…
- Amrutanjan Healt (Q4 FY24)
OTC: ₹108.37 Cr, up 27.57% YoY (Q4 FY23: ₹84.95 Cr) . Key concall takeaways from Amrutanjan Health Care Ltd's Q4 FY24 earnings call — and how it ranks against…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Bharat Parenterals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Bharat Parenterals Ltd Q4 FY24 results?
For Q4 FY 2024, consolidated revenue from operations was INR 67.82 crore, up 13.4% YoY (Q4 FY 2023: INR 59.82 crore). Quarter (Q4 FY 2024) Financials (Consolidated): - EBITDA: ₹3.64 crore, down 53.7% YoY (₹7.87 crore in Q4 FY 2023) - EBITDA margin: 5.17%, down from 12.88% YoY - PAT: -₹2.56 crore, a decrease o
What is Bharat Parenterals Ltd share price analysis?
Bharat Parenterals Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,040 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bharat Parenterals Ltd planning capital expenditure?
Commissioning of two new EU GMP compliant production blocks (Page 15) - Status: Inspection and compliance completed; pending approval - Expected to enable access to multiple APAC geographies - Regulatory approvals underway for Uganda Ministry of Health for existing blocks; plans to obtain approvals in Ethiopia and Tanzania (Page 15) - Infrastructure expansion planned to develop specialty products: lines for lyophilized, pre-filled syringes, and complex emulsion formulations (Page 14) - Current manufacturing facility located in Vadodara, Gujarat with ~28,500 sq.
Keep Bharat Parenterals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.